Literature DB >> 8725998

Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model.

A Valentin1, R Le Guennec, E Rodriguez, J Reynes, M Mallie, J M Bastide.   

Abstract

Relationships between azole susceptibility and in vivo response to antifungal therapy in a murine model of candidiasis were investigated for Candida albicans isolates sampled from human immunodeficiency virus type 1-positive patients with oropharyngeal candidiasis. The susceptibilities of seven clinical isolates and two reference strains to fluconazole (FCZ) and itraconazole (ITZ) were determined in vitro by the broth microdilution method. Four isolates were resistant to FCZ and ITZ, two were susceptible to both azoles, and three were resistant to FCZ and susceptible to ITZ (dissociated resistance). CD1 mice were inoculated with each isolate and treated with either FCZ or ITZ (drug regimen, 5 mg/kg of body weight twice daily for 5 days). Quantitative cultures of kidneys were performed at the end of the treatment. On the other hand, the survival rates of the mice were followed daily. These two parameters were clearly correlated with in vitro susceptibility. Thus, the phenomenon of a dissociation of resistance to FCZ and ITZ may be found in vivo as well as in vitro.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8725998      PMCID: PMC163328          DOI: 10.1128/AAC.40.6.1342

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Reduced virulence of Candida albicans mutants affected in multidrug resistance.

Authors:  J M Becker; L K Henry; W Jiang; Y Koltin
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

Review 2.  Mechanisms and clinical impact of antifungal drug resistance.

Authors:  H Vanden Bossche; D W Warnock; B Dupont; D Kerridge; S Sen Gupta; L Improvisi; P Marichal; F C Odds; F Provost; O Ronin
Journal:  J Med Vet Mycol       Date:  1994

3.  Relationship between fluconazole sensitivity of Candida albicans isolates from HIV positive patients and serotype, adherence and CD4+ lymphocyte count.

Authors:  C Imbert-Bernard; A Valentin; J Reynes; M Mallié; J M Bastide
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-09       Impact factor: 3.267

4.  Correlation between in vitro and in vivo activity of antifungal agents against Candida species.

Authors:  E J Anaissie; N C Karyotakis; R Hachem; M C Dignani; J H Rex; V Paetznick
Journal:  J Infect Dis       Date:  1994-08       Impact factor: 5.226

5.  Reduced virulence of Candida albicans PHR1 mutants.

Authors:  M A Ghannoum; B Spellberg; S M Saporito-Irwin; W A Fonzi
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

6.  In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus.

Authors:  F Barchiesi; A L Colombo; D A McGough; A W Fothergill; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

7.  [Adherence of isolated Candida albicans strains from HIV+ infected patients to buccal epithelial cells: correlation with serotype, sensitivity to fluconazole and virulence].

Authors:  C Imbert-Bernard; A Valentin; J Reynes; M Mallié; J M Bastide
Journal:  Pathol Biol (Paris)       Date:  1994-06

8.  Fluconazole- and itraconazole-resistant Candida albicans strains from AIDS patients: multilocus enzyme electrophoresis analysis and antifungal susceptibilities.

Authors:  R Le Guennec; J Reynes; M Mallié; C Pujol; F Janbon; J M Bastide
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

9.  Fluconazole concentrations in saliva from AIDS patients with oropharyngeal candidosis refractory to treatment with fluconazole.

Authors:  D Garcia-Hermoso; F Dromer; L Improvisi; F Provost; B Dupont
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

10.  Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole.

Authors:  E Bart-Delabesse; P Boiron; A Carlotti; B Dupont
Journal:  J Clin Microbiol       Date:  1993-11       Impact factor: 5.948

View more
  7 in total

1.  Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Authors:  T J Walsh; C E Gonzalez; S Piscitelli; J D Bacher; J Peter; R Torres; D Shetti; V Katsov; K Kligys; C A Lyman
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  High-dose ascorbate with low-dose amphotericin B attenuates severity of disease in a model of the reappearance of candidemia during sepsis in the mouse.

Authors:  Asada Leelahavanichkul; Poorichaya Somparn; Tanabodee Bootprapan; Hongbin Tu; Pattarin Tangtanatakul; Ratchanok Nuengjumnong; Navaporn Worasilchai; Khajohn Tiranathanagul; Somchai Eiam-ong; Mark Levine; Ariya Chinampon; Nattachai Srisawat
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-08-01       Impact factor: 3.619

Review 3.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

4.  Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity.

Authors:  Ashraf S Ibrahim; Brad J Spellberg; Valentina Avenissian; Yue Fu; Scott G Filler; John E Edwards
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

5.  Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro.

Authors:  G P Moran; D J Sullivan; M C Henman; C E McCreary; B J Harrington; D B Shanley; D C Coleman
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

6.  In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.

Authors:  S A Radford; E M Johnson; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

7.  Stable phenotypic resistance of Candida species to amphotericin B conferred by preexposure to subinhibitory levels of azoles.

Authors:  J A Vazquez; M T Arganoza; D Boikov; S Yoon; J D Sobel; R A Akins
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.